Atrial fibrillation burden and clinical outcomes following BTK inhibitor initiation

Bruton’s tyrosine kinase inhibitors (BTKi) have dramatic efficacy against B-cell malignancies, but link with cardiotoxicity, including atrial fibrillation (AF). Burden, severity, and implications of BTKi-related AF are unknown. Leveraging a large-cohort of consecutive B-cell malignancy patients init...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2024-10, Vol.38 (10), p.2141-2149
Hauptverfasser:	Gambril, John Alan, Ghazi, Sanam M., Sansoterra, Stephen, Ferdousi, Mussammat, Kola-Kehinde, Onaopepo, Ruz, Patrick, Kittai, Adam S., Rogers, Kerry, Grever, Michael, Bhat, Seema, Wiczer, Tracy, Byrd, John C., Woyach, Jennifer, Addison, Daniel
Format:	Artikel
Sprache:	eng
Schlagworte:	692/699/1541/1990/283/1895 692/700/565/1436/2185 692/700/565/2194 Adenine - analogs & derivatives Adenine - therapeutic use Agammaglobulinaemia Tyrosine Kinase - antagonists & inhibitors Aged Antiarrhythmics Arrhythmia Atrial Fibrillation - drug therapy Bruton's tyrosine kinase Cancer Research Cardiac arrhythmia Cardiotoxicity Cardiovascular diseases Critical Care Medicine Female Fibrillation Follow-Up Studies Health risks Hematology Humans Intensive Internal Medicine Kinases Lymphocytes B Male Malignancy Medicine Medicine & Public Health Middle Aged Monitoring Mortality Mortality risk Oncology Piperidines - adverse effects Piperidines - therapeutic use Prognosis Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Rhythm Risk factors Tachycardia Tyrosine Ventricle
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!